A space for sharing and discussing news related to global current events, technology, and society.
69462 Members
We'll be adding more communities soon!
© 2020 Relevant Protocols Inc.
A space for sharing and discussing news related to global current events, technology, and society.
69462 Members
We'll be adding more communities soon!
© 2020 Relevant Protocols Inc.
Relevant
Hot
New
Spam
Relevant
Hot
New
Spam
0
3.4K
0
3.4K
>"Israeli study shows Pfizer-BioNTech shot less potent against B.1.351 variant than other COVID-19 mutations."
>"Israeli study shows Pfizer-BioNTech shot less potent against B.1.351 variant than other COVID-19 mutations."
“We found a disproportionately higher rate of the South African variant among people vaccinated with a second dose, compared with the unvaccinated group. This means that the South African variant is able, to some extent, to break through the vaccine’s protection,” said Tel Aviv University’s Adi Stern who led the study.
“We found a disproportionately higher rate of the South African variant among people vaccinated with a second dose, compared with the unvaccinated group. This means that the South African variant is able, to some extent, to break through the vaccine’s protection,” said Tel Aviv University’s Adi Stern who led the study.
Some low-ranking comments may have been hidden.
Some low-ranking comments may have been hidden.